STXBP1 encephalopathy is a genetic neurodevelopmental disorder caused by heterozygous pathogenic variants in STXBP1 (syntaxin-binding protein 1, also known as MUNC18-1). The disorder is characterized by early-onset seizures (often within the first week of life), a distinctive EEG pattern of burst suppression, and profound developmental impairment. STXBP1 is one of the most common genetic causes of early-onset developmental and epileptic encephalopathies (DEEs), accounting for 1-5% of all DEE cases.
The disorder is sometimes called "STXBP1 encephalopathy with epilepsy" to distinguish from STXBP1-related disorders without seizures (which present as non-syndromic intellectual disability). The disease manifests across a spectrum from severe early-onset DEE to milder presentations with later seizure onset and better developmental outcomes.
STXBP1 is critical for synaptic vesicle fusion: it functions as a SM (Sec1/Munc18-like) protein that binds syntaxin-1 and is essential for the SNARE complex assembly that mediates neurotransmitter release[@stxbp1review2023].
¶ Genetics and Molecular Basis
STXBP1 is located on chromosome 9q34.11 and encodes Munc18-1, a 67-kDa protein expressed throughout the brain. The gene spans approximately 120 kb and contains 20 coding exons.
STXBP1 is one of the most intolerant genes in the human genome (pLI = 1.0), reflecting the severe fitness consequence of loss-of-function variants. The majority of pathogenic variants are de novo, though familial cases with gonadal mosaicism or affected parent have been described.
Pathogenic mechanisms include:
- Missense variants (~50%): disrupt Munc18-1 folding, binding to syntaxin, or interactions with other synaptic proteins
- Nonsense/frameshift variants (~40%): premature termination, likely leading to nonsense-mediated decay and haploinsufficiency
- Splice variants (~10%): exon skipping or intron retention
Munc18-1 (encoded by STXBP1) is a master regulator of synaptic vesicle exocytosis. It participates in the synaptic vesicle fusion cascade at multiple levels:
- Synaptic vesicle priming — Munc18-1 is required for the transition of vesicles from a release-ready (primed) state to a fusion-competent state
- SNARE complex formation — Munc18-1 stabilizes the SNARE complex (synaptobrevin, SNAP-25, syntaxin-1) that mediates membrane fusion
- Calcium sensing coordination — Munc18-1 interacts with synaptotagmin to couple calcium influx to vesicle fusion
- Synaptic plasticity — loss disrupts short-term and long-term plasticity mechanisms
The resulting synaptic dysfunction leads to:
- Impaired GABAergic and glutamatergic transmission
- Network hyperexcitability and seizures
- Disrupted activity-dependent circuit formation
- Developmental impairment through both seizure-dependent and independent mechanisms
Most patients present with seizure onset within the first week, often within hours of birth. Seizures are often:
- Tonic (spasms) — most common type
- Focal clonic — rhythmic jerking of one body part
- Myoclonic — brief jerks
- Often frequent and prolonged; status epilepticus in >50%
The EEG characteristically shows burst suppression (alternating periods of high-amplitude bursts and low-amplitude suppression), particularly in the first months. This pattern is reminiscent of Ohtahara syndrome.
¶ Infancy and Early Childhood
Seizure types evolve:
- Tonic seizures (persistent)
- Focal seizures
- Myoclonic seizures
- Atypical absence seizures
- Epileptic spasms (infantile spasms in ~30-40%)
The burst suppression pattern often evolves into ESES (electrical status epilepticus during sleep) or multifocal discharges.
Development is severely impaired from early on. Patients develop:
- Severe intellectual disability
- Hypotonia evolving to spasticity
- Movement disorders (ataxia, dystonia in some)
- Absent or minimal language
- Poor head control, unable to sit independently
¶ Childhood and Beyond
- Seizures persist in most patients, though some have improvement after infancy
- Gross motor development: most never walk independently; some achieve sitting
- Fine motor: hand stereotypies, poor hand use
- Communication: mostly non-verbal or very limited
- Behavior: autism spectrum features common, repetitive behaviors
- Other features: sleep disturbance, feeding difficulties, constipation
- Seizure onset within first year (majority in first week)
- Burst suppression EEG pattern (especially early)
- Profound developmental impairment from early infancy
- Movement disorder (ataxia, dystonia) in a subset
- Family history (usually negative; de novo variant)
- Epilepsy gene panel (first-line): tests STXBP1 and other DEE genes
- Whole exome sequencing (if panel negative): identifies STXBP1 variants
- Targeted STXBP1 sequencing: for clinical suspicion
- Parental testing: critical for genetic counseling (gonadal mosaicism in ~5%)
- Burst suppression in the first months: pathognomonic but not specific to STXBP1
- ESES pattern: emerges in some patients during sleep
- Multifocal epileptiform discharges: as patients age
- Background slowing: progressive disorganization
No specific treatment for STXBP1 encephalopathy; standard ASMs are used:
| Drug |
Evidence |
Notes |
| Benzodiazepines |
Low-moderate |
For acute seizure clusters; limited chronic use |
| Valproic acid |
Low-moderate |
Commonly used; broad spectrum |
| Levetiracetam |
Low |
Limited efficacy |
| Vigabatrin |
Low |
May help spasms |
| Cannabidiol |
Low |
Mixed data |
| Phenobarbital |
Low |
Sometimes effective for neonatal seizures |
Standard ASM approach is trial-and-error; no particular drug class is consistently effective.
- Ketogenic diet: benefit in some refractory cases; mechanism unclear
- Vagus nerve stimulation (VNS): may reduce seizures
- Epilepsy surgery: only for those with identifiable focal seizure onset
- Physical/occupational therapy: supportive care for motor dysfunction
- Communication aids: AAC (augmentative and alternative communication) devices
STXBP1 is an attractive target for gene therapy given:
- Haploinsufficiency mechanism (50% protein reduction may be sufficient for benefit)
- Gene size fits AAV (~2kb coding sequence)
- Early intervention may prevent developmental regression
See clinical trial page for STXBP1 encephalopathy for current preclinical programs.
- Timing: early intervention (before 3-6 months) may be critical given the rapid developmental window
- Dosing: pediatric AAV dosing not well established
- Endpoint: seizure frequency is measurable, but developmental endpoints are challenging
| Outcome |
Details |
| Seizure outcome |
Variable; ~30-40% achieve seizure freedom or significant reduction with age |
| Cognitive outcome |
100% severe to profound ID; most never develop functional language |
| Motor |
Most never achieve independent walking; hypotonia to spasticity, movement disorders |
| Communication |
Minimal or absent; AAC may help |
| Life expectancy |
Not well characterized; respiratory issues, SUDEP risk |
| Behavioral |
Autism features in majority; repetitive behaviors |
- [@stxbp1review2023] STXBP1 encephalopathy: clinical features and molecular basis